Trial: 201905001

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

Phase

II

Principal Investigator

Waqar, Saiama

Disease Site

Corpus Uteri; Ill-Defined Sites; Larynx; Lip, Oral Cavity and Pharynx; Lung; Unknown Sites

Learn more about this study at: clinicaltrials.gov